|  |
| --- |
| **Supplementary table 7: Review question 1 - Child/adolescent symptoms/severity of disease when infected with the alpha variant (n=9)** |
| **Author** | **Study design** | **Country** | **Study setting** | **Number of study participants <20 yo[[1]](#footnote-1)** | **Number of adult study participants** | **Age groups** | **Mean/Median age** | **VOC[[2]](#footnote-2)** | **Symptoms/Severity** | **Comments**  |
| Roberts et al.[14] | case-control study | United Kingdom | schoolskindergartenscrèches | overall: 83infected: 21 | 34 | ≤4yo,adults | n/r | Alpha | **Symptoms** 24% fever, 19% cough(52% asymptomatic) | **sequencing:** 1 case was sequenced, rest was assumed based on date of sampling and national prevalence |
| Ulyte et al. [15] | cohort study | Switzerland | schoolskindergartenscrèches | overall: 2 487newly infected: 182 | n/a | 7-17 yo | median: 12 yo | Alpha | **Symptoms** 17% fatigue (30/182), 17% sore throat (30/182), 15% headache (27/182), 14% fever (26/182) | **sequencing:** n/r |
| Somekh et al.[16] | cross-sectional study | Israel | households | alpha infection: 31non-VOC infection: 20 | n/a | 11-17 yo |  n/r | Alpha | **Symptoms (alpha vs. non-VOC)**sensory impairment: 6.5% (2/31) vs. 40% (8/20)(RR[[3]](#footnote-3): 0.16; 95%CI[[4]](#footnote-4): 0.04–0.6) | **sequencing:** n/r |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Waltenburg et al. [17] | cohort study | USA[[5]](#footnote-5) | households | n/r | n/r | <5 yo,5-11 yo,12-17 yo | median: 12 yo (IQR[[6]](#footnote-6) 7-15) | Alpha | **Symptoms (alpha vs. non-VOC)**constitutional (chills, fever, myalgia):OR[[7]](#footnote-7) 5.5 (95%CI: 1.55-19.20)lower respiratory (e.g. cough):OR 3.52 (95%CI: 1.26-9.86)gastrointestinal (e.g. diarrhoea, pain):OR 3.55 (95%CI: 1.16-10.89)**Severity (alpha vs. non-VOC):**Symptom duration (median, days): 3 vs. 2, p[[8]](#footnote-8) = 0.64 | **vaccination status:** 97% unvaccinated (147/151), 3% partially vaccinated (4/151)**sequencing:** majority of primary cases sequenced |
| Nakel et al.[18] | cohort study | Germany | schoolskindergartenscrèches | infected: 40alpha infection: 18non-VOC infection: 22 | n/a | ≤6 yo | n/r | Alpha | **Symptoms (alpha vs. non-VOC)**fever: 38.9% (7/18) vs. 50% (11/22)cough: 44.4% (8/18) vs. 36.4% (8/22)shortness of breath: 11.1% (2/18) vs. 0% (0/22)**Severity (alpha vs. non-VOC)**ICU[[9]](#footnote-9) admission: 0 vs. 0  | **sequencing:** partially |
| Somekh et al.[19] | cohort study | Israel | hospital inpatients hospital outpatients | alpha infection: 72 796non-VOC infection: 26 689 | n/a | ≤9 yo | n/r | Alpha | **Severity (alpha vs. non-VOC)**Hospitalisation: 0.52% (379/72796) vs. 0.98% (261/26689)RR 0.53 (95% CI: 0.46-0.63), p < 0.001Severe disease/death: 6.9% (26/379) vs. 6.5% (17/261)RR 0.99 (95% CI: 0.96-1.04) | **sequencing:** n/r |
| Swann et al.[20] | cohort study | United Kingdom | hospital inpatients | infected:1 617alpha infection: 952non-VOC infection: 665 | n/a | ≤19 yo | median (alpha): 6.5 yo (IQR 0.3-14.9)median (non-VOC): 4.0 yo (IQR 0.4-13.6) | Alpha | **Symptoms (alpha vs. non-VOC)**fever: 57.1% (544/952) vs. 73.8% (491/665), p<0.001**Severity (alpha vs. non-VOC)**Length of hospitalisation:2 days (IQR 1-4) vs. 2 days (IQR 1-4), p=0.079critical care: 12.0% (109/910) vs. 12.7 (78/616), p=0.989 | **sequencing:** n/r |
| Brookman et al. [21] | cohort study | United Kingdom | hospital outpatients | infected: 80alpha infection: 60non-VOC infection: 20 | n/a | ≤18 yo | n/r | Alpha | **Severity (alpha vs. non-VOC)**Critical disease: 3% (2/60) vs. 20% (4/20)Oxygen: 8% (5/60) vs. 35% (7/20)non-invasive ventilation: 3% (2/60) vs. 15% (3/20)invasive ventilation: 2% (1/60) vs. 20% (4/20) | **sequencing:** n/r |
| Stewart et al.[22] | cohort study | United Kingdom | hospital inpatients | infected: 110alpha infection: 67non-VOC infection: 43 | n/a | <18 yo | median overall: 10.2 yo (IQR 7.6-12.6) | Alpha | **Symptoms (alpha vs. non-VOC)**PIMS-TS[[10]](#footnote-10): 67 vs. 43 casesacute kidney injury in PIMS-TS: 28.4% (19/67) vs. 33% (14/43), p=0.85 | **sequencing:** n/r |

|  |
| --- |
| **Supplementary table 8: Review question 1 - Child/adolescent symptoms/severity of disease when infected with the delta variant (n=13)** |
| **Author** | **Study design** | **Country** | **Study setting** | **Number of study participants <20 yo[[11]](#footnote-11)** | **Number of adult study partici-pants** | **Age groups** | **Mean/Median age** | **VOC[[12]](#footnote-12)** | **Symptoms/Severity** | **Comments**  |
| Li et al.[23] | cohort study | China | hospital inpatients | infected: 77 | n/a | <12 yo | median:9 yo | Delta | **Symptoms** 75.3% fever (58/77), 18.2% cough (14/77), 7.8% expectoration (6/77) | **sequencing:** alleveryone was hospitalised for isolation |
| Hao et al. [24] | cohort study | China | hospital inpatients | infected: 66 | n/a | ≤18 yo | mean (±SD[[13]](#footnote-13)): 10.35±5.86 yo | Delta | **Symptoms**47.0% fever (31/66), 47.0% cough (31/66), 34.8% nasal congestion (23/66), 25.8% sore throat (17/66), 10.6% fatigue (7/66), 4.5% decreased sense of smell (3/66) | **Sequencing:** n/r |
| Nygaard et al.[25] | cohort study | Denmark | hospital inpatients | infected: 74delta infection :51non-VOC infection: 23  | n/a | ≤17 yo | n/r | Delta | **MIS-C**[[14]](#footnote-14) **symptoms (delta vs. non-VOC)**hypotension/shock: 51% (26/51) vs. 57% (13/23)cardiac involvement: 90% (46/51) vs. 100% (23/23)gastrointestinal involvement: 98% (50/51) vs. 100% (23/23)respiratory involvement: 12% (6/51) vs. 26% (6/23)**MIS-C severity (delta vs. non-VOC)**ICU[[15]](#footnote-15) admission: 55% (28/51) vs. 52% (12/23)vasoactive support: 16% (8/51) vs. 22% (5/23)no need for mechanical ventilation or ECMO[[16]](#footnote-16), no deaths for both delta and non-VOC infection(risk of MIS-C comparable with delta and non-VOC infection) | **vaccination status:** none vaccinated**sequencing:** majority sequenced |
| Murillo-Zamora et al. [26] | cohort study | Mexico | hospital inpatients | infected: 26 961person-days: 297 099 | n/r | ≤19 yo | mean (±SD):14.4±5.8 yo | Delta | **Severity (delta vs. pre-delta)**pneumonia: incidence rate 30.3/10 000 person-days vs. 9.4/10 000 person-daysRR[[17]](#footnote-17) 0.98 (95%CI: 0.97-0.99), p[[18]](#footnote-18)<0.001 | **sequencing:** n/rno information on pre-delta strains |
| Ryu et al. [27] | cohort study | South Korea | population | infected: 235delta infection: 92pre-delta infection: 143 | n/r | <18 yo | mean (delta): 10.2 yomean (pre-delta): 13.8 yop<0.001  | Delta | **Symptoms (delta vs. pre-delta)**rhinorrhoea: 10.5% (15/143) vs. 25% (23/92), p=0.003nasal stuffiness: 15.4% (22/143) vs. 34.8% (32/92), p=0.001sore throat: 12.6% (18/143) vs. 23.9% (22/143), p=0.02no difference in prevalence of other COVID symptoms (e.g. fever, cough, pneumonia) | **sequencing:** n/rno information on pre-delta strains |
| Fisman et al. [28] | cohort study | Canada | population | infected:20 434delta infection:12 387non-VOC infection:8 047 | n/a | ≤19 yo | n/r | Delta | **Severity (delta vs. non-VOC)**hospitalization (<10 yo): OR[[19]](#footnote-19) 2.51 (95%CI: 1.23-5.11)hospitalization (10-19 yo): OR 0.78 (95%CI: 0.38-1.91) ICU admission (10-19 yo): OR 1.37 (95%CI: 0.11-16.46) | **sequencing:** all sequenced |
| Shoji et al.[29] | cohort study | Japan | hospital inpatients | infected:1 299delta infection:349pre-delta infection:950 | n/a | <18 yo | median (delta): 7.0 yo (IQR[[20]](#footnote-20): 2-13)median (pre-delta): 10.0 yo (IQR: 4-15)p<0.001 | Delta | **Severity (delta vs. pre-delta)**ICU admission: 1.4% (5/349) vs. 0.1% (1/950), p=0.006length of hospitalisation (median, days): 7.0 (IQR 5.0-9.0) vs. 8.0 (IQR 5.0-9.0), p=0.031mechanical ventilation: 0% vs. 0% | **sequencing:** n/rno information on pre-delta strains |
| Martin et al. [30] | cohort study | USA[[21]](#footnote-21) | hospital inpatientshospital outpatients | infected:167 262delta infection:29 191pre-delta infection:138 071 | n/a | <19 yo | median (delta): 10.3 yo (IQR 5.3-14.9)median (pre-delta): 12.3 yo (IQR 6.2-16.4) | Delta | **Severity (delta vs. pre-delta)**hospitalisation: 6.0% (1738/29191) vs. 6.2% (8507/138071), p=0.18severe disease: 10.3% (179/1738) vs. 14.6% (1242/8507), (OR 0.67, 95%CI: 0.57-0.79), p<0.001severe disease (children classified as non-black, non-white): OR 1.69 (95%CI: 1.02-2.82, p=0.04 | **sequencing:** n/rno information on pre-delta strains |
| Butt et al.[31] | cohort study | Qatar | population | infected:246delta infection:125beta infection:121 | n/a | ≤19 yo | n/a | Beta,Delta | **Symptoms (delta vs. beta)**moderate disease: aOR[[22]](#footnote-22) 0.17 (0.06-0.48) vs. 0.35 (0.09-1.39), p=0.54severe disease: aOR 0.08 (0.01-0.48) vs. NA, p>0.99 | **sequencing:** all sequenced |
| Molteni et al.[32] | cohort study | United Kingdom | population | infected:1 400delta infection:7065-11 yo:22712-17 yo: 479alpha infection:6945-11 yo: 27612-17 yo: 418 | n/r | 5-17 yo | median (alpha): 12 yo (IQR 9-15)median (delta): 14 yo (IQR 13-16) | Alpha,Delta | **Symptoms (delta vs. alpha)**5-11yo headache: 60.8% (138/227) vs. 39.9% (110/276), OR 2.31 (95%CI: 1.6-3.33), p<0.001fever: 46.3% (105/227) vs. 31.9% (88/276), OR 1.89 (95%CI: 1.31-2.73) (p=0.001)12-17yoheadache: 73.7% (353/479) vs. 61.5% (257/418), OR 1.81 (95%CI: 1.36-2.42), p<0.001fever: 43.2% (207/479) vs. 27.0% (113/418), OR 2.05 (95%CI: 1.55-2.72), p<0.001rhinorrhoea: 57.6% (276/479) vs. 47.4% (198/418), OR 1.52 (95%CI: 1.17-1.98), p=0.002sore throat: 60.5% (290/479) vs. 45.7% (191/418), OR 1.87 (95%CI: 1.43-2.45), p<0.001**Severity (delta vs. alpha)**symptom burden (5-11 yo, median/days): 4 (IQR 2-7) vs 3 (IQR 2-5)symptom burden (12-17 yo, median/days): 6 (IQR 3-9) vs 5 (IQR 3-8) | **sequencing:** n/r |
| Kildegaardet al.[33] | cohort study | Denmark | Hospital inpatients and outpatients | infected:74 611alpha infection: n/rdelta infection: n/r | n/a | <18 yo | Median (infected): 8 yo (IQR 1-14) | Alpha,Delta | **Severity (alpha vs. delta)**hospitalization: RR[[23]](#footnote-23) 0.49% (98/20102) (95%CI[[24]](#footnote-24): 0.4-0.59) vs. 0.48% (18/16694) (95%CI: 0.38-0.6)MIS-C: RR 0.04% (9/20164) (95%CI: 0.02-0.08) vs. 0.04% (5/12778) (95%CI: 0.01-0.09) | **vaccination status:** partially vaccinated**sequencing:** n/r |
| Çelebi et al.[34] | cohort study | Turkey | hospital inpatientshospital outpatients | infected:680alpha infection:329beta/gamma infection: 17delta infection:165non-VOC infection:169  | n/a | ≤17 yo | median:9.25 yo  | Alpha,Beta,Delta | **Severity (alpha vs. delta vs. beta/gamma vs. non-VOC)**hospitalization: 9.4% (31/329) vs. 19.4% (32/165) vs. 18% (3/17) vs. 10.1% (17/169) **Severity (alpha vs. delta)**hospitalization: 9.4% (31/329) vs. 19.4% (32/165), p=0.016**Severity (delta vs. non-VOC)** hospitalization: 19.4% (32/165) vs. 10.1% (17/169), p=0.002 | **sequencing:** all sequenced, but no differentiationbetween gamma and beta |
| Edward et al.[35] | cohort study | USA | hospital outpatients | infected: 499alpha infection:96gamma infection:38delta infection:119non-VOC infection:243 | n/a | ≤18 yo | median (alpha): 9 yo (IQR 2-14)median (gamma): 7 yo (IQR 1-14)median (delta): 4 yo (IQR 1-11)median (non-VOC): 7 yo (IQR 1-12) | Alpha,Delta,Gamma  | **Symptoms (alpha vs. gamma vs. delta vs. non-VOC)**symptomatic: 91.6% (88/96) vs. 89.4% (34/38) vs. 89.9% (107/119) vs. 91.7% (223/243), p=0.92**Severity - Hospitalization**non-VOC: 3.2% (8/243) reference alpha: 7.2% (7/96): OR 1.9 (95%CI: 0.59-6.3)gamma: 15.7% (6/38): OR 5.9 (95%: 1.6-21.5), p=0.007delta: 6.7% (8/119): OR 2.2 (95%CI: 0.69-7.7) **ICU admission**non-VOC: 1.2% (3/243): referencealpha: 1.0% (1/96) :OR 0.47 (95%CI: 0.02-4.0)gamma: 5.2% (2/38): OR 2.6 (95%CI: 0.31-17.5)delta: 2.5% (3/119): OR 1.4 (95%CI: 0.24-9.0)**Respiratory support**non-VOC: 1.2% (3/243): referencealpha: 0% : OR 0gamma: 10.5% (4/38) : OR 8.3 (95%CI: 1.5-56.3), p=0.02delta: 2.5% (3/119) : OR 2.2 (95%CI: 0.34-16.9) | **sequencing:** all sequenced |

|  |
| --- |
| **Supplementary table 9: Review question 1 - Child/adolescent symptoms/severity of disease when infected with the omicron variant (n=11)** |
| **Author** | **Study design** | **Country** | **Study setting** | **Number of study participants <20 yo[[25]](#footnote-25)** | **Number of adult study partici-pants** | **Age groups** | **Mean/Median age** | **VOC[[26]](#footnote-26)** | **Symptoms/severity** | **Comments**  |
| Cloete et al.[36] | cohort study | South Africa | hospital inpatients | infected: 139 | n/a | ≤13 yo | n/r | Omicron | **Symptoms**47% fever, 40% cough, 24% vomiting, 23% difficulty breathing, 20% convulsions**Severity**hospitalization: 92% standard ward care, 25% oxygen therapy, 2% high flow oxygen, 6% ventilation | **sequencing:** partially sequenced |
| Brewster et al. [37] | cohort study | USA[[27]](#footnote-27) | hospital inpatients, hospital outpatients | infected: 75 omicron: 61pre-omicron: 14 | n/a | n/r | median (omicron):ED[[28]](#footnote-28): 2.4 yo (0.8–2.6) hospitalized: 1.6 yo (0.7–1.1)median (pre-omicron):ED: 2.6 yo (1.6–3.4)hospitalized: 1.3 yo (1.1–1.5) | Omicron | **Symptoms (omicron vs. pre-omicron):**Croup: 81% (61/75) vs. 19% (14/75) Median weekly croup cases(omicron vs. pre-omicron):11 [IQR[[29]](#footnote-29) 2–17] vs. 0 (IQR 0-0), p[[30]](#footnote-30) < 0.001none required invasive ventilation or died (irrespective of variant) | **sequencing:** n/r |
| Ludvigsson et al.[38]  | case series (>1 case) | Sweden | hospital inpatients | infected: 3 | n/r | <15 yo | n/r | Omicron | **SymptomsCase 1:** repeated convulsions over several hours, hospitalisation: 4 days**Case 2:** status epilepticus, hospitalisation: 2 days**Case 3:** one convulsion (30-60sec), short behavioural change, hospitalisation: 2 days | **sequencing:** n/r14yo: clinical diagnosis |
| Butt et al. [39] | cohort study | Qatar | population | Infected: 985 (both the omicron and delta cohort) | n/r | <18 yo | median (delta): 7 yo (IQR 3-9)median (omicron): 6 yo (IQR 3-10) | Delta, Omicron | **Severity (omicron vs. delta)** mild/not hospitalised: 97.8% (963/985) vs. 84.2% (829/985), p<0.001moderate disease: 2.2% (22/985) vs. 15.7% (155/985)critical disease: 0% (0/985) vs. 0.1% (1/985) moderate+critical disease: 2.2% (22.985) vs. 15.8% (156/985), p<0.001, aOR[[31]](#footnote-31) 0.12 (95%CI: 0.07-0.18) | **vaccination status:** none vaccinated**sequencing:** n/r |
| Fowlkes et al. [40] | cohort study | USA | population | infected: 252omicron infection: 150delta infection: 102 | n/r | 5-11 yo,12-15 yo | n/r | Delta, Omicron | **Symptoms (omicron vs. delta)**COVID[[32]](#footnote-32)- symptoms: 48.7% (73/150) vs. 65.7% (67/102); OR[[33]](#footnote-33) 2.0 (95%CI[[34]](#footnote-34): 1.2-3.45), p=0.008**‘Severity (omicron vs. delta)**total days of symptoms: 5.4% vs. 8.0%; OR -3.4 (95%CI: (-)5.7 - (-)1.0), p=0.006hours of missed school: 21.8% vs. 24.1%**;** OR -10.6 (95%CI: (-)18.6 - (-)2.7), p=0.01(no differences in febrile symptoms, received medical care, days spent sick in bed) | **vaccination status:** 5-11 yo: 65% (682/1052) double vaccinated, 7% (69/1052) 1 dose, and 29% (301/1052) unvaccinated. 12–15 yo: 68% (212/312) double vaccinated, 5% (15/312) 1 dose, 27% (85/312) unvaccinated**sequencing:** n/r |
| Wang et al.[41] | cohort study | USA | hospital inpatientshospital outpatients | infected: 7 198 (both the omicron and the delta cohort) | n/r | <5 yo | mean (omicron):1.49±1.42 mean (delta):1.48±1.42 | Delta, Omicron | **Severity (omicron vs. delta)**ED visits: 18.83 %(1355/7198) vs. 26.67 (1920/7198); RR[[35]](#footnote-35) 0.71 (95% CI: 0.66-0.75)hospitalisation: 1.04% (75/7198) vs. 3.14 (226/7198); RR 0.33 (95%CI: 0.26-0.43)ICU[[36]](#footnote-36) admission: 0.14% (10/7198) vs. 0.43% (31/7198); RR 0.32 (95%CI: 0.16-0.66)mech. ventilation: 0.33% (24/7198) vs. 1.15% (83/7198); RR 0.29 (95%CI: 0.18-0.46) | **sequencing:** n/r |
| Wang et al.[42] | cohort study | USA | hospital inpatientshospital outpatients | infected ≤4 yo: 11 556 (both the omicron and the delta cohort)infected 5-17 yo: 18 715(both the omicron and the delta cohort) | n/a | ≤4 yo,5-17yo | n/a | Delta, Omicron | **Severity (omicron vs. delta)**≤ 4yoED visits: 20.41% (2359/11556) vs. 23.96% (2796/1156); RR 0.85 (95%CI: 0.81-0.89)hospitalization: 1.55% (179/11556) vs. 3.0% (347/11556); RR 0.52 (95%CI: 0.43-0.62)ICU admissions: 0.1% (12/11556) vs. 0.42% (49/11556); RR 0.25 (95%CI: 0.13-0.46)mech. ventilation: 0.09% (10/11556) vs. 0.2% (23/11556); RR 0.44 (95%CI: 0.21-0.91)5-17yoED visits: 10.09% (1889/18715) vs. 13.07% (2446/18715); RR 0.77 (95%CI: 0.73-0.82)hospitalization: 0.77% (144/18715) vs. 1.37% (144/18715); RR 0.56 (95%CI: 0.46-0.69)ICU admissions: 0.23% (43/18715) vs. 0.38% (71/18715); RR 0.61 (95%CI: 0.42-0.88)mech. ventilation: 0.05% (10/18715) vs. 0.06 (11/18715); RR 0.91 (95%CI: 0.39-2.14) | **sequencing:** n/r**vaccination status:** n/r |
| Marks et al.[43] | cohort study | USA | hospital inpatients | infected: 2 100omicron infection: 266delta infection: 1 834 | n/r | ≤4 yo,5-11 yo,12-17yo  | median: 7 yo (IQR 1-14) | Delta, Omicron | **Severity (omicron vs. delta)**ICU admission (≤17 yo): 20.2% (52/266) vs. 27.8% (510/1834)mech. ventilation (≤17 yo): 2.3% (6/266) vs. 6.3% (112/1834)hospitalization (≤4yo): 54.2% (142/266) vs. 42.5% (778/1834); RR 5.4 (95%CI: 4.0-7.2) hospitalization (5-11 yo): 16.9% (43/266) vs. 22.5% (417/1834); RR 2.3 (95%CI: 1.5-3.6)hospitalization (12–17 yo): 28.9% (81/266) vs. 34.9% (639/1834); RR 3.5 (95%CI: 2.5-5.0) | **sequencing:** n/r**vaccination status:** n/r |
| Iuliano et al.[44]  | cross-sectional study | USA | hospital inpatients | infected: 824omicron infection: 405delta infection: 272non-VOC infection: 147 | n/a | ≤17 yo | n/r | Delta, Omicron | **Severity (omicron vs. delta)**ICU admission: 10.4% (42/405) vs. 18.4% (50/272)(ICU admission non-VOC: 17.0% (25/147))  | **sequencing:** n/r**vaccination status:** n/r  |
| Shi et al.[45] | cross-sectionalstudy | USA | hospital inpatients | infected: 1 475omicron infection:397delta infection:482pre-Delta infection: 596 | n/a | 5-11 yo | median: 8 yo (IQR 6-10) | Delta, Omicron | **Severity (omicron vs. delta)**ICU admission: 18.9% vs. 26.1%, p=0.05 mech. ventilation: 4.6% vs. 6.8%, p=0.28death: 0% vs. 0%**Severity (omicron vs. pre-delta)**ICU admission pre-Delta: 18.9% vs. 32.6%, p<0.01mech. ventilation: 4.6% vs. 6.7%, p=0.28death: 0%. vs. 0.7% **underlying diseases (omicron vs. delta):**neurologic disorders: 33% vs. 21%, p<0.01obesity: 33% vs. 21%, p = 0.01 | **sequencing:** n/r**vaccination status:** n/r |
| Markset al.[46] | cohort study | USA | Hospital inpatients | infected:2 562omicron infection: 572delta infection: 790pre-delta infection: 1 200 | n/a | ≤4 yo | median:0.6yo (IQR 0.1–1.0) | Delta, Omicron | **Severity (omicron vs. delta vs. pre-delta):** length of hospitalisation (days, median, IQR): 1.5 (0.5-2.5) vs. 2 (1-3.5) vs. 1.5 (1-3.5), p (omicron vs. pre-delta)= 0.001,p (omicron vs. delta)=0.002ICU admission: 21.0 % vs. 26.7% vs. 24%, p (omicron vs. pre-delta)= 0.19, p (omicron vs. delta)=0.02BiPAP/CPAP[[37]](#footnote-37): 5.1% vs. 9.1% vs. 5.9%, p (omicron vs. pre-delta)= 0.53, p (omicron vs. delta)=0.008high flow nasal canula: 13.4% vs. 20.4% vs. 8.3%, p (omicron vs. pre-delta)= 0.002, p (omicron vs. delta)=0.002No difference in invasive mechanical ventilation and in hospital deaths | **vaccination status:** none vaccinated**sequencing:** n/r |

|  |
| --- |
| **Supplementary table 10: Review question 1 - Child/adolescent symptoms/severity of disease when infected with the gamma variant (n=2)** |
| **Author** | **Study design** | **Country** | **Study setting** | **Number of study participants <20 yo[[38]](#footnote-38)** | **Number of adult study participants** | **Age groups** | **Mean/Median age** | **VOC[[39]](#footnote-39)** | **Symptoms/Severity** | **Comments**  |
| Oliveira et al. [47] | cohort study | Brazil | hospital inpatients | infected:21 591gamma infection:10 017non-VOC infection:11 574 |  n/r | <20 yo | mean (gamma):4.0 yo (IQR[[40]](#footnote-40) 0.6 - 14.7)mean (non-VOC):5.2 yo (IQR 1.0 - 14.4) | Gamma | **Severity (gamma vs. non-VOC)**hypoxemia: 52.5% vs. 41.1%, p[[41]](#footnote-41)<0.0001ICU[[42]](#footnote-42) admissions: 28.3% (2498/8830) vs. 24.9% (2745/11037), p<0.0001invasive vent. support: 10.1% (974/9659) vs. 10.8% (1156/10733) p<0.0001 | **sequencing:** n/r |
| Edward et al. [48] | cohort study | USA[[43]](#footnote-43) | hospital outpatients | infected: 499alpha infection: 96gamma infection: 38delta infection: 119non-VOC infection: 243 | n/a | ≤ 18 yo | median (alpha): 9 yo (IQR 2-14)median (gamma): 7 yo (IQR 1-14)median (delta): 4 yo (IQR 1-11)median (non-VOC): 7 yo (IQR 1-12) | Alpha, Delta, Gamma  | **Symptoms (alpha vs. gamma vs. delta vs. non-VOC)**symptomatic: 91.6% (88/96) vs. 89.4% (34/38) vs. 89.9% (107/119) vs. 91.7% (223/243), p=0.92**Severity - Hospitalization**non-VOC: 3.2% (8/243) reference alpha: 7.2% (7/96): OR[[44]](#footnote-44) 1.9 (95%CI[[45]](#footnote-45): 0.59-6.3)gamma: 15.7% (6/38): OR 5.9 (95%: 1.6-21.5), p=0.007delta: 6.7% (8/119):OR 2.2 (95%CI: 0.69-7.7)**ICU admission**non-VOC: 1.2% (3/243): referencealpha: 1.0% (1/96): OR 0.47 (95%CI: 0.02-4.0)gamma: 5.2% (2/38): OR 2.6 (95%CI: 0.31-17.5)delta: 2.5% (3/119): OR 1.4 (95%CI: 0.24-9.0)**Respiratory support**non-VOC: 1.2% (3/243): referencealpha: 0%: OR 0gamma: 10.5% (4/38): OR 8.3 (95%CI: 1.5-56.3), p=0.02delta: 2.5% (3/119) OR 2.2 (95%CI: 0.34-16.9) | **sequencing:** all sequenced |

|  |
| --- |
| **Supplementary table 11: Review question 3 - Child/Adolescent risk of becoming infected with a SARS-CoV-2 variant of concern (n=15)** |
| **Author** | **Study design** | **Country** | **Study setting** | **Number of contacts <20 yo[[46]](#footnote-46)** | **Number of adult contacts** | **Age groups** | **Mean/Median age** | **VOC[[47]](#footnote-47)** | **Risk of infection compared to non-VOCs/other VOCs** | **Risk of infection compared to adults** | **Comments**  |
| Schenk et al.[50] | cohort study | Germany | schoolskindergartenscrèches | non-VOC: 577 alpha: 756 | non-VOC: 334alpha: 226 | ≤7 yo,adults | median: 4yo | Alpha | **Risk of infection (alpha vs. non-VOC)**0% (0/756) vs. 1.2% (7/577) | **Risk of infection (children vs. adults)**0% (0/756) vs. 0% (0/226) | **vaccination status:** n/r**sequencing:** n/r |
| Neubergeret al.[51] | cross-sectional study | Germany | schoolskindergartenscrèches | n/r8500 early childhood education and care centres | n/r | ≤2 yo,4-6 yo,≥7 yo, adults | n/r | Alpha | n/a | **Risk of infection (children vs. adults)** higher absolute case number, but overall rate of infection still higher in adults | **vaccination status:** n/r**sequencing:** n/r |
| Nakelet al.[18] | cohort study | Germany | schoolskindergartenscrèches | 113 | 31 | ≤6 yo | n/r | Alpha | **Risk of infection (alpha vs. non-VOC)**15.9% (18/113) vs. 64.7% (22/34) | **Risk of infection****(children vs. adults)**15.9% (18/113) vs. 35.5% (11/31) | **vaccination status:** n/r**Sequencing:** few cases sequenced, presence of variant assumed for the rest based on date of sampling and national prevalence |
| Robertset al.[14] | case-control study | United Kingdom | schoolskindergartenscrèches | 83 | 34 | ≤4 yo,adults | n/r | Alpha | n/a | **Risk of infectionAR**[[48]](#footnote-48) **(children vs. adults)**25.3% (21/83) vs. 70.6% (24/34) **AR (children):**- 0-1yo: 44%- 1-2 yo: 31%- 2-3yo: 31%- 3-4 yo: 4% | **vaccination status:** n/r**sequencing:** 1 case sequenced, presence of variant assumed for the rest based on date of sampling and national prevalence |
| Loenenbach et al.[52] | cohort study | Germany | schoolskindergartenscrèches | 133 | 60 | ≤6 yo,adults | n/r | Alpha | n/a | **Risk of infectionSAR**[[49]](#footnote-49) **overall (children vs. adults)**21.1% (28/133) vs. 31.7% (19/60)**SAR per daycare centre (children vs. adults)**1. 31% (15/49) vs. 53% (10/19)2. 27% (7/26) vs. 28% (5/18)3. 17% (6/36) vs. 17% (4/23) | **vaccination status:** n/r**sequencing:** n/r |
| Lorthe et al.[53] | cohort study | Switzerland | schoolskindergartenscrèches | 70 | 9 | 4-6 yo,adults | n/r | Alpha | n/a | **Risk of infectionAR (children vs. adults)**27.4% (22/70) vs. 22.2% (2/9)**AR (children by classes)** 1. 62.9% (13/21)2. 10.5% (2/19)3. 16.7% (3/18)4. 13.3% (2/15) | **vaccination status:** n/r**sequencing:** all cases |
| Abu-Raddadet al.[54] | cohort study | Qatar | population | 55 638<10 yo: 28 79110-19 yo: 26 847 | 30-39yo: 81 760  | <10 yo,10-19 yo,adults | n/r | Alpha | n/a | **Risk of infection (children <10 yo vs. adults)**1.7% (502/28791) vs. 3.6% (2966/81760)OR[[50]](#footnote-50) 0.35 (95%CI[[51]](#footnote-51): 0.32–0.39)**Risk of infection (adolescents 10-19 yo vs. adults)**3.6% (965/26847) vs. 3.6% (2966/81760) | **vaccination status:** n/r**sequencing:** 85% of all cases sequenced |
| Somekh et al.[19] | cohort study | Israel | hospital inpatientshospital outpatients | 72 426Alpha: 50 811non-VOC: 21 615 | n/r | <10 yo | n/r | Alpha | **Risk of infection(alpha vs. non-VOC)**slope of weekly adjusted incidence:84.4 (95%CI: 71.1- 97.7) vs39.1 (95%CI:23.9-54.3) | n/a | **sequencing:** n/r |
| Somekh et al.[16] | cross-sectional study | Israel | households | Alpha: 77non-VOC: 58 | n/r | ≤5 yo,6-17 yo | n/r | Alpha | **Risk of infection (alpha vs. non-VOC)**≤5 yo: 72% (18/25) vs. 11.1% (2/18)RR[[52]](#footnote-52) 7.8 (95%CI: 2.1–29.0)6-17 yo: 75% (39/52) vs. 32.5% (13/40) RR 2.5 (95%CI: 1.6–4.0) | n/a | **sequencing:** n/r |
| Waltenburg et al.[17] | cohort study | USA[[53]](#footnote-53) | households | Alpha :61non-VOC : 39 | n/r | ≤11 yo,12-17 yo | Median :12 yo (IQR[[54]](#footnote-54) 7-15) | Alpha | **Risk of infection (alpha vs. non-VOC)**64% (39/61) (95%CI: 51-76) vs. 56% (22/39) (95%CI: 40-72);OR 1.08 (95% CI: 0.40- 2.98)**(≤11 yo vs. 12-17yo)**78% (21/27) (95%CI: 58-91) vs. 53% (18/34) (95%CI: 35-70);OR 1.37 (95%CI:0.61-3.04) | n/a | **vaccination status:** 97% unvaccinated (147/151), 3% partially vaccinated (4/151)**sequencing:** majority of primary cases sequenced |
| Clifford et al.[55] | cohort study | United Kingdom | households | 67 | 406 | <18 yo,adults | n/r | Delta | n/a | **Risk of infection (children vs. adults)**RR 0.84 (95%CI: 0.66-0.99)(risk of being infected by non-elderly adults) | **vaccination status:** n/r**sequencing:** 63.1% of cases sequenced, rest was assumed based on date of sampling and national prevalence |
| Ng et al. [56] | cohort study | Singapore | households | 1 136 | 7223 | ≤11 yo,12-17 yo, adults | median :36 yo (IQR 26-51) | Delta | n/a | **Risk of infectionSAR (≤11 yo vs. 18-29 yo)**22.9% (173/757) vs. 12.0% (212/1765) ;aOR[[55]](#footnote-55) 1.43 (95%CI: 1.07-1.93), p=0.017**SAR (12-17 yo vs. 18-29 yo)**12.9% (49/379) vs. 12.0% (212/1765) ;aOR 0.97 (95%CI: 0.66-1.42), p[[56]](#footnote-56)=0.87 | **vaccination status:** >12 yo partially vaccinated (results adjusted for vaccination status)**sequencing:** partially sequenced |
| Dougherty et al.[57] | cohort study | USA | camps,sport clubs | 122 | 11 | <12 yo,12-19 yo,adults | median: 14 yo (IQR 5-58) | Delta | n/a | **Risk of infection AR (children vs. adults)**18.9% (23/122) vs. 27.3% (3/11) | **vaccination status:** majority unvaccinated/partially vaccinated**sequencing:** 21 sequenced, rest was assumed based on date of sampling and national prevalence |
| Singana-yagam et al.[58] | cohort study | United Kingdom | community | 30 | 198 | 5-18 yo,adults | median: 41 yo(IQR 28-49) | Delta | n/a | **Risk of infectionSAR (children vs. adults)**40% (12/30) vs. 20.1% (41/198) | **vaccination status:** 70% were fully vaccinated, 23.7% were partially vaccinated, 23% were not vaccinated**sequencing:** partially sequenced, rest was assumed based on date of sampling and national prevalence |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lorthe et al.[59] | Cohort study | Switzerland | schoolskindergartenscrèches | 59 | 10 | 3-7 yo,adults | n/r | Omicron |  | **Risk of infectionAR (children vs. adults)**44.1% (26/59) vs. 50% (5/10)**AR (children by classes)**1. 33.3% (4/12)2. 15.4% (2/13)3. 56.3% (9/16)4. 61.1% (11/18) | **vaccination status:** n/r**sequencing:** none  |

|  |
| --- |
| **Supplementary table 12: Review question 4 - Risk of child/adolescent transmission when infected with a SARS-CoV-2 variant of concern (n=15)** |
| **Author**  | **Study design** | **Country** | **Study setting** | **Number of index cases <20 yo[[57]](#footnote-57)** | **Number of adult index cases** | **number of contacts of children/adolescents** | **number of contacts of adults** | **Age groups** | **Mean/Median age** | **VOC[[58]](#footnote-58)** | **Risk of transmission compared to non-VOCs/other VOCs** | **Risk of transmission compared to adults** | **Comments**  |
| Lindstromet al.[60] | cohort study | Norway | population | 42alpha: 14non-VOC: 28  | 373alpha: 131non-VOC: 242  | mean (SD[[59]](#footnote-59)): 2.79 (1.63) | 40-59yo:1.72 (1.87)20-39yo:1.03 (1.36)>60yo: 1.25 (1.65) | <20 yo,adults | n/r | Alpha | n/a | **Transmission risk SAR**[[60]](#footnote-60) **(<20 yo vs. 40-59 yo)**ref. vs. 1.97 (1.08-3.87)no significant difference to adults 20-39 yo, >60yo | **vaccination status:** n/r**sequencing:** primary cases sequenced, variants in contacts assumed based on date of sampling and national prevalence |
| Lyngse et al.[61] | cohort study | Denmark | households | 145<10 yo:5410-19 yo: 91 | 663 | 383<10yo: 14110-19yo: 242 | 1 336 | ≤10 yo,10-20 yo,adults | n/r | Alpha | n/a | **Transmission riskAR**[[61]](#footnote-61) **(≤20 yo vs. adults)**32.4% (124/383) vs. 39.8% (532/1336)**AR (≤10 yo vs. 10-19 yo vs. adults)**45% (64/141) vs. 25% (60/242) vs. 39.8% (532/1336) | **vaccination status:** n/r**sequencing:** 75% sequenced, rest was assumed based on date of sampling and national prevalence |
| Chudasama et al. [62] | cohort study | United Kingdom | households | 6 011<10 yo: 1 28910-19 yo: 4 722 | 57 382 | n/r | n/r | <10 yo,10-19 yo,adults | n/r | Alpha | n/a |  **Transmission riskOR[[62]](#footnote-62) (10-19 yo vs. <10 yo)** OR 0.83 (95%CI[[63]](#footnote-63): 0.69-0.99)(<10 yo: reference)no difference in transmission risk compared to index cases aged 30-70 yo | **vaccination status:** n/r**sequencing:** all index cases sequenced, no information on contacts |
| Julin et al. [63] | cohort study | Norway | households | 3alpha: 2non-VOC: 1 | 55alpha: 16non-VOC: 39 | 55alpha: 16non-VOC: 39 | 68alpha: 20non-VOC: 48 | <20 yo,adults | median: 31 yo (IQR[[64]](#footnote-64) 2-73) | Alpha | n/a | **Transmission risk (irrespective of VOC)Viral loads (mean, <20 yo vs. adults)**2.09 log10 copies/ul RNA[[65]](#footnote-65) vs. 2.98 log10 copies/ul RNA **Length of testing positive (mean days, <20 yo vs. adults)**11.3 (95%CI: 7.6–15.1) vs 16.4 (95%CI: 13.5–19.3), p[[66]](#footnote-66) = 0.03 | **vaccination status:** none vaccinated**sequencing:** all sequenced |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Loenenbachet al.[52] | cohort study | Germany | schoolskindergartenscrècheshouseholds | 22 | 16 | 59 | 33 | ≤6 yo,adults | n/r | Alpha | n/a | **Transmission riskSAR[[67]](#footnote-67) (≤6 yo vs. adults)**39% (95%CI: 28-52) vs. 33% (95%CI: 20-50)RR[[68]](#footnote-68) 1.17 (95%CI: 0.66-2.09) | **vaccination status:** n/r**sequencing:** n/r |
| Lortheet al.[53] | cohort study | Switzerland | schoolskindergartenscrècheshouseholds | n/r | n/r | 24 | 2 | ≤6 yo,adults | n/r | Alpha | n/a | **Transmission riskSAR (≤6 yo vs. adults)**12.5% (3/24) vs. 50% (1/2) | **vaccination status:** n/r**sequencing:** all cases |
| Loss et al.[64] | case-control study | Germany | schoolskindergartenscrècheshouseholds | 15alpha:9non-VOC: 6 | 9alpha:4non-VOC: 5 | 172alpha: 114non-VOC: 58 | 38 | ≤6 yo,adults | n/r | Alpha | **Transmission riskAR[[69]](#footnote-69) (alpha vs. non-VOC)**16.7% (19/114) vs. 8.6% (5/58) | **Transmission riskAR (≤6 yo vs. adults)**16.7% (19/114) vs. 10.5% (4/38) | **vaccination status:** n/r**sequencing:** majority sequenced, rest was assumed based on date of sampling and national prevalence |
| Buchan et al.[65] | cohort study | Canada | households | 715<10 yo alpha: 55non-VOC: 19510-19 yo alpha: 114non-VOC: 351 | 4 902alpha: 1 149non-VOC: 3 753 | n/r | n/r | <10 yo,10-19 yo,adults | n/r | Alpha | **Transmission riskSAR (alpha vs. non-VOC)**aRR[[70]](#footnote-70) (<10y o): 1.47 (95%CI: 0.81-2.65) aRR (10-19 yo): 1.30 (95%CI: 0.80-2.10) | n/a | **sequencing:** all cases either sequenced or screened positive for N501Y (marker for alpha variant) by PCR[[71]](#footnote-71) |
| Waltenburget al. [17] | cohort study | USA[[72]](#footnote-72) | households | 36alpha: 21non-VOC: 10 | n/a | 111alpha :61non-VOC : 39 | n/a | <5 yo5-11 yo12-17 yo | median:12 yo (IQR 7-15) | Alpha | **Transmission risk SAR (alpha vs. non-VOC)**55% (24/44) (95%CI: 39-70) vs. 46% (12/26) (95%CI: 27-67); OR 1.52 (95%CI: 0.51-4.53)**SAR – alpha(≤11 yo vs. 12-17 yo)**65% (11/17) (95%CI: 38-68) vs. 48% (13/27) (95%CI: 29-68); OR 1.63 (95%CI: 0.4-6.7) | n/a | **vaccination status:** 97% unvaccinated (147/151), 3% partially vaccinated (4/151) (2 primary cases and 2 secondary cases)**sequencing:** majority of primary cases sequenced |
| Ratman et al. [66] | modeling study | USA | population | n/a | n/a | n/a | n/a | <10 yo,10-19 yo | n/r | Alpha | **Transmission riskR**[[73]](#footnote-73) **(alpha vs. non-VOC)**<10yo: <1 vs. <<110-19 yo: ~1 vs. <<1 | n/a | n/a |
| Somekhet al.[19] | cohort study | Israel | hospital inpatientshospital outpatients | 72 426alpha: 50 811non-VOC:21 615(overall numbers and thus potential index cases) | n/r | alpha: 313 871non-VOC: 156 521 | n/r | <10 yo | n/r | Alpha | **Transmission riskAR (alpha vs. non-VOC)**15.7% (49257/313871) vs. 7.5% (11770/156521) RR: 2.24 (95%CI, 2.20-2.29), p < 0.001  | n/a | **sequencing:** n/r |
| Allenet al. [67] | case-control study | United Kingdom | households | 6 130alpha: n/rdelta: n/r | 17 928 | n/r | n/r | <10 yo,10-19 yo,adults | n/r | Alpha,Delta | n/a | **Trasmission riskaOR[[74]](#footnote-74)(delta vs. alpha/ref. adults)**<10 yo: 0.98 (95%CI: 0.85-1.14) 10-19 yo: 0.71 (95%CI: 0.64-0.79) (reference value 1.00 for 30-39 yo) | **vaccination status:** reported (but not in subanalysis comparing transmission risk in age groups)**sequencing:** all index cases sequenced, nationwide 50% of all cases were sequenced at time of study |
| Trobajo-Sanmartinet al.[68] | cohort study | Spain | population | n/r | n/a | All contacts of <12 yo :288Alpha : 107Delta : 181 | n/a | <12yo,12-17 yo,adults | n/r | Alpha,Delta | **Transmission risk SAR(alpha vs. delta)**<12 yo : 33% (35/107) vs. 23% (41/181); aRR 1 vs. 0.58 (95%CI: 0.28-1.23), p=0.155higher risk of transmission for 12-39yo |  | **vaccination status:** none vaccinated**sequencing:** none |
| Ng et al.[56] | cohort study | Singapore | households | n/r | n/r | 472 | 18-29 yo : 1 467 | ≤11 yo,12-17 yo,adults | median (contacts):36 yo (IQR 26-51) | Delta | n/a | **Transmission risk****SAR (≤11 yo vs. 18-29 yo)**25.2% (88/349) vs. 9.4% (138/1457);aOR: 2.37 (95%CI:1.57-3.60), p<0.0001**SAR (12-17 yo vs. 18-29 yo)**17.9% (22/123) vs. 9.4% (138/1457) ; aOR 1.81 (95%CI: 0.91-3.6), p=0.089 | **vaccination status:** >12 yo partially vaccinated (results adjusted for vaccination status)**sequencing:** partially sequenced |
| Lorthe et al.[59] | cohort study | Switzerland | schoolskindergartenscrèches, households | n/r | n/a | 52 | n/a | 3-7 yo,adults | n/r | Omicron | **Transmission risk SAR**48% (25/52) | n/a | **vaccination status:** n/r**sequencing:** none  |

1. yo: years old [↑](#footnote-ref-1)
2. VOC: Variants Of Concern [↑](#footnote-ref-2)
3. RR: Risk Ratio [↑](#footnote-ref-3)
4. 95%CI: 95% Confidence Interval [↑](#footnote-ref-4)
5. USA: United States of America [↑](#footnote-ref-5)
6. IQR: Interquartile Range [↑](#footnote-ref-6)
7. OR: Odd Ratio [↑](#footnote-ref-7)
8. p: p-value [↑](#footnote-ref-8)
9. ICU: Intensive Care Unit [↑](#footnote-ref-9)
10. 6PIMS-TS/MIS-C: Paediatric Inflammatory Multisystem Syndrome/Multisystem Inflammatory Syndrome in Children [↑](#footnote-ref-10)
11. yo: years old [↑](#footnote-ref-11)
12. VOC: Variants Of Concern [↑](#footnote-ref-12)
13. SD: Standrad Deviation [↑](#footnote-ref-13)
14. MIS-C: Multisystem Inflammatory Syndrome in Children [↑](#footnote-ref-14)
15. ICU: Intensive Care Unit [↑](#footnote-ref-15)
16. ECMO: Extracorporeal Membrane Oxygenation [↑](#footnote-ref-16)
17. RR: Risk Ratio [↑](#footnote-ref-17)
18. p: p-value [↑](#footnote-ref-18)
19. OR: Odd Ratio [↑](#footnote-ref-19)
20. IQR: Interquartile Range [↑](#footnote-ref-20)
21. USA: United States of America [↑](#footnote-ref-21)
22. aOR: Adjusted Odd Ratio [↑](#footnote-ref-22)
23. RR: Risk Ratio [↑](#footnote-ref-23)
24. 95%CI: 95% Confidence Interval [↑](#footnote-ref-24)
25. yo: years old [↑](#footnote-ref-25)
26. VOC: Variants Of Concern [↑](#footnote-ref-26)
27. USA: United States of America [↑](#footnote-ref-27)
28. ED: Emergency Department [↑](#footnote-ref-28)
29. IQR: Interquartile Range [↑](#footnote-ref-29)
30. p: p-value [↑](#footnote-ref-30)
31. aOR: Adjusted Odd Ratio [↑](#footnote-ref-31)
32. COVID: Coronavirus Disease [↑](#footnote-ref-32)
33. OR: Odd Ratio [↑](#footnote-ref-33)
34. 95%CI: 95% Confidence Interval [↑](#footnote-ref-34)
35. RR: Risk Ratios [↑](#footnote-ref-35)
36. ICU: Intensive Care Units [↑](#footnote-ref-36)
37. BiPAP/CPAP: Bilevel Positive Airway Pressure/ Continuous Positive Airway Pressure [↑](#footnote-ref-37)
38. yo: years old [↑](#footnote-ref-38)
39. VOC: Variant Of Concern [↑](#footnote-ref-39)
40. IQR: Interquartile Range [↑](#footnote-ref-40)
41. p: p-value [↑](#footnote-ref-41)
42. ICU: Intensive Care Unit [↑](#footnote-ref-42)
43. USA: United States of America [↑](#footnote-ref-43)
44. OR: Odds Ratio [↑](#footnote-ref-44)
45. 95%CI: 95% Confidence Interval [↑](#footnote-ref-45)
46. yo: years old [↑](#footnote-ref-46)
47. VOC: Variant Of Concern [↑](#footnote-ref-47)
48. AR : Attack Rate [↑](#footnote-ref-48)
49. SAR: Secondary Attack Rate [↑](#footnote-ref-49)
50. OR: Odd Ratio [↑](#footnote-ref-50)
51. 95%CI: 95% Confidence Interval [↑](#footnote-ref-51)
52. RR: Risk Ratio [↑](#footnote-ref-52)
53. USA: United States of America [↑](#footnote-ref-53)
54. IQR: Interquartile Range [↑](#footnote-ref-54)
55. aOR: adjusted Odd Ratio [↑](#footnote-ref-55)
56. p: p-value [↑](#footnote-ref-56)
57. yo: years old [↑](#footnote-ref-57)
58. VOC: Variant Of Concern [↑](#footnote-ref-58)
59. SD: Standard Deviation [↑](#footnote-ref-59)
60. SAR: secondary attack rate [↑](#footnote-ref-60)
61. AR: attack rate [↑](#footnote-ref-61)
62. OR: Odd Ratio [↑](#footnote-ref-62)
63. 95%CI: 95% Confidence Interval [↑](#footnote-ref-63)
64. IQR: Interquartile Range [↑](#footnote-ref-64)
65. RNA: Ribonucleic acid [↑](#footnote-ref-65)
66. p: p-value [↑](#footnote-ref-66)
67. SAR: Secondary Attack Rate [↑](#footnote-ref-67)
68. RR: Risk Ratio [↑](#footnote-ref-68)
69. AR: Attack Rate [↑](#footnote-ref-69)
70. aRR: Adjusted Risk Ratio [↑](#footnote-ref-70)
71. PCR: Polymerase Chain Reaction [↑](#footnote-ref-71)
72. USA: United States of America [↑](#footnote-ref-72)
73. R: reproduction number [↑](#footnote-ref-73)
74. aOR: Adjusted Odd Ratio [↑](#footnote-ref-74)